Agent Capital

Carisma Therapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative cellular immunotherapies for the treatment of solid tumors. Founded in 2016, the company specializes in engineering chimeric antigen receptor (CAR) macrophages and monocytes, which are types of white blood cells that play a crucial role in the immune response. By harnessing advances in macrophage biology and adoptive cell transfer, Carisma aims to enhance cancer therapies, allowing for more effective treatment options for patients with solid tumors. The company is in the clinical stage of development, working to translate its proprietary technology into transformative therapies for various serious diseases.

Vittoria Biotherapeutics develops gene-edited cell therapies. they provide next-generation, paradigm-shifting T-cell therapeutics that address unmet medical needs. Senza5 Technology from viTToria improves the efficacy, safety, and utility of cell-based treatments in preclinical settings.

Carisma Therapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative cellular immunotherapies for the treatment of solid tumors. Founded in 2016, the company specializes in engineering chimeric antigen receptor (CAR) macrophages and monocytes, which are types of white blood cells that play a crucial role in the immune response. By harnessing advances in macrophage biology and adoptive cell transfer, Carisma aims to enhance cancer therapies, allowing for more effective treatment options for patients with solid tumors. The company is in the clinical stage of development, working to translate its proprietary technology into transformative therapies for various serious diseases.

Carisma Therapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative cellular immunotherapies for the treatment of solid tumors. Founded in 2016, the company specializes in engineering chimeric antigen receptor (CAR) macrophages and monocytes, which are types of white blood cells that play a crucial role in the immune response. By harnessing advances in macrophage biology and adoptive cell transfer, Carisma aims to enhance cancer therapies, allowing for more effective treatment options for patients with solid tumors. The company is in the clinical stage of development, working to translate its proprietary technology into transformative therapies for various serious diseases.

Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer.

Carisma Therapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative cellular immunotherapies for the treatment of solid tumors. Founded in 2016, the company specializes in engineering chimeric antigen receptor (CAR) macrophages and monocytes, which are types of white blood cells that play a crucial role in the immune response. By harnessing advances in macrophage biology and adoptive cell transfer, Carisma aims to enhance cancer therapies, allowing for more effective treatment options for patients with solid tumors. The company is in the clinical stage of development, working to translate its proprietary technology into transformative therapies for various serious diseases.